Last reviewed · How we verify
Adalimumab every other week
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Adalimumab every other week |
|---|---|
| Also known as | HUMIRA |
| Sponsor | Innovaderm Research Inc. |
| Drug class | TNF-α inhibitor |
| Target | TNF-α (tumor necrosis factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
TNF-α is a key pro-inflammatory cytokine that drives immune-mediated inflammation in autoimmune and inflammatory diseases. By blocking TNF-α, adalimumab suppresses the inflammatory cascade and reduces tissue damage. The every-other-week dosing regimen maintains therapeutic drug levels while optimizing patient convenience and compliance.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
- Plaque psoriasis
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Tuberculosis reactivation
- Opportunistic infections
- Malignancy risk
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis (PHASE3)
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
- Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis (PHASE3)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
- An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (PHASE2)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |